Results 111 to 120 of about 13,123 (252)

Prophylactic HIPEC in high-risk colorectal cancer: do we really need a randomized clinical trial to prove a “logical” hypothesis? [PDF]

, 2021
Rodrigo Oliva Perez, Adrián Mattacheo, Pieter J. Tanis   +2 more
openalex   +1 more source

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC

Annals of Surgical Oncology, 2019
BackgroundKRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy ...
W. Graf, P. Cashin, L. Ghanipour, M. Enblad, J. Botling, A. Terman, H. Birgisson   +6 more
semanticscholar   +1 more source

Are positron emission tomography-computed tomography (PET-CT) scans useful in preoperative assessment of patients with peritoneal disease before cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)? [PDF]

, 2017
Weining Wang, Grace Hwei Ching Tan, Claramae Shulyn Chia, Thakshayeni Skanthakumar, Khee Chee Soo, Melissa Ching Ching Teo   +5 more
openalex   +1 more source

Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China

Orphanet Journal of Rare Diseases
Background To explore the application value of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei (PMP). Methods We retrospectively analyzed the clinical data of 526 patients
Bing Wang, Ruiqing Ma, Guanjun Shi, Xiwen Fan, Benqiang Rao, Hongbin Xu   +5 more
doaj   +1 more source

Cytoreductuctive surgery and HIPEC

, 2017
Systemic treatment alone is no longer appropriate for patients with limited peritoneal dissemination from primary or recurrent colon cancer. A clinical pathway for the management of these patients should include cytoreductive surgery and HIPEC. There are four specific problems that have to be resolved in the future in order to improve survival of the ...
Kekez, Tihomir, Kinda, Emil, Jelinčić, Željko, Majerović, Mate, Golem, Ante Zvonimir, Silovski Hrvoje, Augustin, Goran, Matošević, Petar, Bruketa, Tomislav, Bogdanić, Branko, Majsec Budak, Ana   +10 more
openaire   +3 more sources

HIPEC for ovarian cancer

, 2021
Eierstokkanker staat in de top 10 van kankerdiagnoses bij vrouwen wereldwijd. Ongeveer 70-80% van de patiënten met eierstokkanker, heeft deze ziekte in stadium III of IV, waarbij de ziekte is uitgezaaid naar het buikvlies of buiten de buikholte. De behandeling van eierstokkanker bestaat uit chirurgie, chemotherapie en doelgerichte onderhoudstherapie ...
openaire   +2 more sources

Application of HIPEC simulations for optimizing treatment delivery strategies [PDF]

, 2023
Daan R. Löke, H. Petra Kok, Roxan F.C.P. Helderman, Bella Bokan, Nicolaas A.P. Franken, Arlene L. Oei, Jurriaan B. Tuynman, Pieter J. Tanis, Johannes Crezee   +8 more
openalex   +1 more source

Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials

Annals of Surgical Oncology, 2022
B. L. Green, A. Blumenthaler, Lauren A Gamble, James D. Mcdonald, K. Robinson, Maureen Connolly, Monica Epstein, Jonathan M. Hernandez, A. Blakely, B. Badgwell, Jeremy L. Davis   +10 more
semanticscholar   +1 more source

EP297/#520 Is routine admission to a critical care unit following HIPEC for ovarian cancer necessary? [PDF]

, 2022
Ruby M. van Stein, Lot Aronson, Florine J. Hendriks, Aletta Houwink, Peter Schütte, Cor D. de Kroon, Gabe S. Sonke, Willemien J. van Driel   +7 more
openalex   +1 more source

Long-term outcomes after cytoreductive surgery and HIPEC for morcellated uterine leiomyosarcoma; A case series

, 2021
Maya Yasukawa, Louis A. Dainty, Paul H. Sugarbaker   +2 more
openalex   +1 more source